Search
Close this search box.

A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Primary Sponsor

Collaborating Groups

TROG Cancer Research

Accrual Target

412

Final Accrual

415

Closing Date of Accrual

20 August 2024

Trial Chairperson

Prof Sandro Porceddu - Princess Alexandra Hospital

Trial Contact

qa@trog.com.au

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof